Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Dendritic cells and the control of immunity

1998 • 14,345 citations

Cancer statistics, 1999

1999 • 3,154 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1998 • 2,373 citations

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes

1998 • 2,078 citations

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

1996 • 1,854 citations

A Southwest Oncology Group study

1993 • 778 citations

Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

1999 • 604 citations

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells

1997 • 596 citations

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1996 • 398 citations

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

1993 • 314 citations

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1998 • 266 citations

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1990 • 207 citations

Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.

1997 • 128 citations

Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide

1998 • 114 citations

A Pilot Clinical Trial of HIV Antigen-Pulsed Allogeneic and Autologous Dendritic Cell Therapy in HIV-Infected Patients

1998 • 109 citations

Suramin-Induced Decrease in Prostate-Specific Antigen Expression With No Effect on Tumor Growth in the LNCaP Model of Human Prostate Cancer

1996 • 97 citations

Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses

1990 • 90 citations

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–-genitourinary group study 30853

1993 • 86 citations

Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody

1989 • 51 citations

Dendritic Cell Based Therapy of Cancer

1997 • 45 citations

A quantitative model of autoimmune disease and T-cell vaccination: does more mean less?

1995 • 40 citations

Systemic treatment for prostate cancer

1998 • 37 citations

Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide National prostatic cancer project randomized trial☆

1988 • 28 citations

Induction of autoantibody responses to GM-CSF by hyperimmunization with an Id-GM-CSF fusion protein.

1995 • 27 citations

Induction of Hapten-specific B Cell Tolerance by Low Doses of Hapten-Carrier Conjugate

1973 • 23 citations

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

1993 • 22 citations